Company Monitoring Page for Alexion

latest headlines for company on cafepharma

Jazz Pharma, Lundbeck and Alexion Pay $122 Million to Settle Kickback Allegations
BioSpace
Thu, 04/4/19 - 11:02 pm
Tags:
Jazz Pharma, Lundbeck, Alexion, kickbacks, charity
Alexion chief registers $16.5M in pay after a solid year, with a relatively low 74-to-1 ratio compared to a well paid staff
Endpoints
Tue, 03/26/19 - 10:15 am
Tags:
Alexion, Pharma CEOs, executive pay, Ludwig Hantson
14 Drugs Earn Billions for These Massachusetts Biotechs
BioSpace
Wed, 03/6/19 - 09:59 am
Tags:
Massachusetts, Boston, Biogen, Tecfidera, Benepali, Shire, Takeda, Vyvanse, Vertex Pharmaceuticals, Orkambi, Kalydeco, Alexion, Soliris, Strensiq, Sanofi Genzyme, Lantus, Ironwood Pharmaceuticals, Linzess
Alexion runs toward big Ultomiris goals with early Soliris switching success
Fierce Pharma
Tue, 02/5/19 - 11:17 pm
Tags:
Alexion, Ultomiris, paroxysmal nocturnal hemoglobinuria, PNH
Based On Sales Forecasts For 2018 FDA Approved Drugs, Big Pharma Not Just Focused On Blockbusters
Forbes
Mon, 01/28/19 - 11:00 am
Tags:
Big Pharma, Pfizer, Merck, AstraZeneca, Gilead Sciences, Alexion, Vertex Pharmaceuticals
JPM recap: Must-reads of the week, from FDA to IPO to M&A and more
Fierce Pharma
Fri, 01/11/19 - 10:25 am
Tags:
JPMHC 2019, Merck, FDA, M&A, Celgene, Bristol-Myers Squibb, Genevant, IPOs, Eli Lilly, Novartis, GSK, Teva Pharmaceutical, Alexion, Pear Therapeutics
FDA approves new Alexion’s therapy targeting paroxysmal nocturnal hemoglobinuria
GoinPharma
Fri, 12/28/18 - 01:00 pm
Tags:
Alexion, FDA, ALXN1210, Ultomiris, PNH
5 Top Drug/Biotech Merger & Acquisition Targets for 2019
Yahoo/Zacks.com
Mon, 12/10/18 - 09:50 am
Tags:
M&A, Biomarin, Vertex Pharmaceuticals, Incyte, Alnylam, Alexion
Alexion to buy biotech firm Syntimmune for up to $1.2 billion
Reuters
Wed, 09/26/18 - 07:24 pm
Tags:
Alexion, Syntimmune, M&A
Alexion’s Soliris wows in rare disease PhIII trial, opening up a new franchise worth $500M-$700M
Endpoints
Mon, 09/24/18 - 03:33 pm
Tags:
Alexion, Soliris, clinical trials, NMOSD
FDA Accepts Priority Review of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria
CP Wire
Mon, 08/20/18 - 11:40 am
Tags:
Alexion Pharmaceuticals, Alexion, FDA, ALXN210, PNH, paroxysmal nocturnal hemoglobinuria
Vertex and Alexion Are Schooling Big Biotech
Washington Post, DC
Fri, 07/27/18 - 11:19 pm
Tags:
earnings, Vertex Pharmaceuticals, Alexion
Could Amgen soften the Neulasta biosimilar blow with an Alexion buy?
Fierce Pharma
Mon, 07/16/18 - 10:34 pm
Tags:
Amgen, biosimilars, Neulasta, Alexion, M&A
How badly does Alexion want its Soliris follow-on? Enough to use a rare fast pass
Biopharma Dive
Tue, 06/19/18 - 09:40 pm
Tags:
Alexion, Soliris, fast pass, FDA, priority review, ALXN1210
Big Biotech Set for Earnings Blowout?
Barron's
Sat, 06/16/18 - 01:24 pm
Tags:
biotech, earnings, Gilead Sciences, Alexion, Vertex Pharmaceuticals
Alexion snags option to buy neurodegeneration startup Complement
Fierce Biotech
Mon, 06/11/18 - 10:01 pm
Tags:
Alexion, Complement Pharma, M&A
With $460B in borrowing capacity, will any of the Big-20 biopharmas go after one of the top-5 takeover targets?
Endpoints
Tue, 05/29/18 - 09:22 pm
Tags:
M&A, JNJ, Merck, Pfizer, Gilead Sciences, Amgen, Biogen, Takeda, Regeneron, Alexion
Biopharma M&A: You Ain’t Seen Nothing Yet
Barron's
Fri, 05/25/18 - 09:32 am
Tags:
JNJ, Merck, Pfizer, Gilead Sciences, Amgen, Regeneron, Alexion, M&A
Alexion buying Swedish biotech for $855 million to broaden rare disease pipeline
Stat
Wed, 04/11/18 - 11:10 am
Tags:
Alexion, WIlson Therapeutics, M&A, Rare Diseases
When Will They Learn? 4 Huge Biotech Blowups
Motley Fool
Thu, 03/29/18 - 09:24 pm
Tags:
biotech, AstraZeneca, ZS-9, drug manufacturing, Alexion, Synageva, Merck, Cubist Pharmaceuticals, AbbVie, Rova-T, Stemcentrx

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.